When is telavancin used to treat enterococcal infections?

Updated: Jun 10, 2021
  • Author: Susan L Fraser, MD; Chief Editor: John L Brusch, MD, FACP  more...
  • Print
Answer

Telavancin is a novel lipoglycopeptide that is rapidly bactericidal against a broad spectrum of aerobic and anaerobic gram-positive pathogens, including many Enterococcus species. [54, 55] Telavancin was approved by the FDA on September 11, 2009, for the treatment of adult patients with complicated skin and skin structure infection due to numerous aerobic gram-positive organisms, including vancomycin-susceptible isolates of E faecalis. Although its activity against many vancomycin-resistant isolates of Enterococcus is good, especially against VanB strains of enterococci, it is currently not FDA-approved for the treatment of infections caused by vancomycin-resistant strains. Dalbavancin is a new lipoglycopeptide antibiotic that is structurally related to vancomycin and teicoplanin. It was approved by the FDA in May 2014 for gram-positive bacteria including Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant Staphylococcus aureus [MRSA]), Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus anginosus group (including S anginosus, S intermedius, S constellatus). It also has activity against non-VRE enterococci, but is not yet approved for this indication. It has a very long half-life that allows IV administration to be given as a 2-dose, once weekly regimen.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!